Stock Whisper
Long only, value, growth, growth at reasonable price

Pimavanserin Calls For Better Valuations For Acadia

ACADIA Pharmaceuticals (NASDAQ:ACAD), a biopharmaceutical company, recently announced their third quarter financial results on November 6, after the market close. The company announced the attainment of various clinical milestones, over the quarter. The share prices of ACADIA dipped almost 7% before the earnings release due to the rumors, which were proved correct, that the losses of the firm will widen in the third quarter.

ACADIA saw a substantial up-rise in its stock prices since the beginning of 2013. This was attributed to the positive clinical trial results of Pimavanserin, a potential treatment for Parkinson's disease psychosis (NASDAQ:PDP). The FDA in April agreed to cancel the phase III-021 confirmatory trial for Pimavanserin, owing to the positive results...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details